Osteoporosis is a prevalent systemic metabolic disorder characterized by a reduction in bone mass and bone density, damage in microstructure of bone tissue, and raised bone fragility causing of fracture susceptibility. This study included 189 Iraqi adults aged 45–75 years, evaluating serum levels TGF-β3 and WNT5A across three groups: healthy individuals (n = 31) as control, those with primary osteoporosis/osteopenia (n = 61), and with comorbidity-related osteoporosis (linked to β-thalassemia, parathyroid disorders or diabetes; n = 97). Among those, β-thalassemia-associated osteoporosis patients showed the most distinct decrease in bone mineral density (0.57 ± 0.078 g/cm², p < 0.0001) along with marked increases in WNT5A (0.89 ± 0.68). Based on disease context, the level of TGF-β3 varied, peaking in thalassemia cases (0.28 ± 0.18 ng/mL). Significant disease-specific correlations were noticed, comprising moderate positive relationships between TGF-β3 and WNT5A (r = 0.433, p = 0.017) in diabetes patients, as well as a negative correlation between HbA1c and TGF-β3 in diabetes (r = −0.503, p = 0.047). Receiver Operating Characteristic (ROC) analysis highlighted WNT5A (AUC ≤ 0.882, sensitivity ≤ 81%) and TGF-β3 (AUC ≤ 0.891) as effective biomarkers for distinguishing thalassemia-related osteoporosis. These results underscore the role of comorbidities in altering stress response and signaling pathways, and support the use of WNT5A and TGF-β3 as promising diagnostic markers for targeted osteoporosis management in high-risk populations.
Keywords
Comorbidity-Driven Bone LossOsteopeniaOsteoporosisTGF-β3WNT5A Signalling.
References
Y.-Y. Zhang, N. Xie, X.-D. Sun, E. C. Nice, Y.-C. Liou, C. Huang, et al., “Insights and implications of sexual dimorphism in osteoporosis,” Bone Research, vol. 12, p. 8, 2024.
Y.-J. Chen, L.-H. Jia, T.-H. Han, Z.-H. Zhao, J. Yang, J.-P. Xiao, et al., “Osteoporosis treatment: current drugs and future developments,” Frontiers in Pharmacology, vol. 15, p. 1456796, 2024.
R. Rizzoli and T. Chevalley, “Nutrition and osteoporosis prevention,” Current Osteoporosis Reports, vol. 22, pp. 515-522, 2024.
Q. Li, J. Wang, and C. Zhao, “From genomics to metabolomics: molecular insights into osteoporosis for enhanced diagnostic and therapeutic approaches,” Biomedicines, vol. 12, p. 2389, 2024.
C. Qiu, F. Yu, K. Su, Q. Zhao, L. Zhang, C. Xu, et al., “Multi-omics data integration for identifying osteoporosis biomarkers and their biological interaction and causal mechanisms,” iScience, vol. 23, p. 100847, 2020.
X. Cheng, X. Zhou, C. Liu, and X. Xu, “Oral osteomicrobiology: the role of oral microbiota in alveolar bone homeostasis,” Frontiers in Cellular and Infection Microbiology, vol. 11, p. 751503, 2021.
T.-L. Ma, P. Zhu, Z.-R. Ke, J.-X. Chen, Y.-H. Hu, and J. Xie, “Focusing on OB-OC-MΦ axis and miR-23a to explore the pathogenesis and treatment strategy of osteoporosis,” Frontiers in Endocrinology, vol. 13, p. 891313, 2022.
E. Haghighizadeh, M. Shahrezaee, S. R. Sharifzadeh, and M. Momeni, “Transforming growth factor-β3 relation with osteoporosis and osteoporotic fractures,” Journal of Research in Medical Sciences, vol. 24, p. 46, 2019.
E. Wei, M. Hu, L. Wu, X. Pan, Q. Zhu, H. Liu, et al., “TGF-β signaling regulates differentiation of MSCs in bone metabolism: Disputes among viewpoints,” Stem Cell Research & Therapy, vol. 15, p. 156, 2024.
A. L. Guerrerio, A. Mateja, M. Rasooly, S. Levin, A. Magnani, C. Dempsey, et al., “Predictors of low bone density and fracture risk in Loeys–Dietz syndrome,” Genetics in Medicine, vol. 24, pp. 419-429, 2022.
Y. Huang, Q. Xue, J. Chang, X. Wang, and C. Miao, “Wnt5a: A promising therapeutic target for inflammation, especially rheumatoid arthritis,” Cytokine, vol. 172, p. 156381, 2023.
Y. Zhao, C. Zhang, Y. Huang, Y. Yu, R. Li, M. Li, et al., “Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-κB signaling in the granulosa cells of PCOS patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, pp. 201-211, 2015.
A. Soliman, M. Yassin, F. Alyafei, N. Alaaraj, N. Hamed, S. Osman, et al., “Nutritional studies in patients with β-thalassemia major: A short review,” Acta Bio Medica: Atenei Parmensis, vol. 94, p. e2023187, 2023.
R. Chen and R. Armamento-Villareal, “Obesity and skeletal fragility,” The Journal of Clinical Endocrinology & Metabolism, vol. 109, pp. e466-e477, 2024.
K. Gkastaris, D. G. Goulis, M. Potoupnis, A. D. Anastasilakis, and G. Kapetanos, “Obesity, osteoporosis and bone metabolism,” Journal of Musculoskeletal & Neuronal Interactions, vol. 20, p. 372, 2020.
M. Yamamoto and T. Sugimoto, “Advanced glycation end products, diabetes, and bone strength,” Current Osteoporosis Reports, vol. 14, pp. 320-326, 2016.
L. Karim and M. L. Bouxsein, “Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties,” Bone, vol. 82, pp. 21-27, 2016.
M. Sanchez-Villalobos, M. Blanquer, J. M. Moraleda, E. J. Salido, and A. B. Perez-Oliva, “New insights into pathophysiology of β-thalassemia,” Frontiers in Medicine, vol. 9, p. 880752, 2022.
M. De Martinis, A. Allegra, M. M. Sirufo, A. Tonacci, G. Pioggia, M. Raggiunti, et al., “Vitamin D deficiency, osteoporosis and effect on autoimmune diseases and hematopoiesis: a review,” International Journal of Molecular Sciences, vol. 22, p. 8855, 2021.
F. Romano, D. Serpico, M. Cantelli, A. Di Sarno, C. Dalia, R. Arianna, et al., “Osteoporosis and dermatoporosis: a review on the role of vitamin D,” Frontiers in Endocrinology, vol. 14, p. 1231580, 2023.
R. Vlashi, X. Zhang, M. Wu, and G. Chen, “Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders,” Genes & Diseases, vol. 10, pp. 1291-1317, 2023.
K. Bao, Y. Jiao, L. Xing, F. Zhang, and F. Tian, “The role of Wnt signaling in diabetes-induced osteoporosis,” Diabetology & Metabolic Syndrome, vol. 15, p. 84, 2023.
C. Li, H. Gong, P. Shi, S. Liu, and Q. Zhang, “Different forms of regulated cell death in type-2-diabetes-mellitus-related osteoporosis: A focus on mechanisms and therapeutic strategies,” International Journal of Molecular Sciences, vol. 26, p. 4417, 2025.
G. Leanza, F. Cannata, M. Faraj, C. Pedone, V. Viola, F. Tramontana, et al., “Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength,” eLife, vol. 12, p. RP90437, 2024.
G. Marcucci, V. Domazetovic, C. Nediani, J. Ruzzolini, C. Favre, and M. L. Brandi, “Oxidative stress and natural antioxidants in osteoporosis: novel preventive and therapeutic approaches,” Antioxidants, vol. 12, p. 373, 2023.
T. Iantomasi, C. Romagnoli, G. Palmini, S. Donati, I. Falsetti, F. Miglietta, et al., “Oxidative stress and inflammation in osteoporosis: molecular mechanisms involved and the relationship with microRNAs,” International Journal of Molecular Sciences, vol. 24, p. 3772, 2023.
Y. A. Fakhri and A. W. Al-Ani, “Association of superoxide dismutase with ticagrelor treatment in patients with peripheral arterial disease,” Iraqi Journal of Science, vol. 66, pp. 1812-1823, 2025.
H. A. Hasan and A. W. Al-Ani, “Superoxide dismutase activity in breast cancer patients treated with anastrozole,” Onkologia i Radioterapia, vol. 17, pp. 1-10, 2023.
A. W. Al-Ani, “Adenosine deaminase and guanine deaminase: The potential role in diabetic foot ulcers,” Iraqi Journal of Science, vol. 64, pp. 5826-5837, 2023.
N. J. Mohamed and A. W. Al-Ani, “Evaluation of ornithine decarboxylase and ferric reducing capacity levels as potential biomarkers for polycystic ovary syndrome,” Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, vol. 19, pp. 145-154, 2025.
K. Maeda, Y. Kobayashi, N. Udagawa, S. Uehara, A. Ishihara, T. Mizoguchi, et al., “Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis,” Nature Medicine, vol. 18, pp. 405-412, 2012.
M. Almeida, L. Han, T. Bellido, S. C. Manolagas, and S. Kousteni, “Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT,” Journal of Biological Chemistry, vol. 280, pp. 41342-41351, 2005.
U. Baschant, S. Altamura, P. Steele-Perkins, M. U. Muckenthaler, M. V. Spasić, L. C. Hofbauer, et al., “Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss,” Trends in Endocrinology & Metabolism, vol. 33, pp. 652-663, 2022.
V. Jeney, “Clinical impact and cellular mechanisms of iron overload-associated bone loss,” Frontiers in Pharmacology, vol. 8, p. 77, 2017.
E. Voskaridou, D. Christoulas, A. Papatheodorou, C. Bratengeier, E. Plata, D. Kaliontzi, et al., “High circulating levels of sclerostin correlate with bone mineral density in patients with thalassemia and osteoporosis: the role of the Wnt signaling in the pathogenesis of bone loss in thalassemia,” Blood, vol. 116, p. 1010, 2010.
E. Umur, S. B. Bulut, P. Yiğit, E. Bayrak, Y. Arkan, F. Arslan, et al., “Exploring the role of hormones and cytokines in osteoporosis development,” Biomedicines, vol. 12, p. 1830, 2024.
L. Wang, M. Ruan, Q. Bu, and C. Zhao, “Signaling pathways driving MSC osteogenesis: mechanisms, regulation, and translational applications,” International Journal of Molecular Sciences, vol. 26, p. 1311, 2025.
H. Datta, W. Ng, J. Walker, S. Tuck, and S. Varanasi, “The cell biology of bone metabolism,” Journal of Clinical Pathology, vol. 61, pp. 577-587, 2008.
·
This work is licensed under a
Creative Commons Attribution-ShareAlike 4.0 International License
